PubMed Health⌕ Search

Biomedical subjects

Konrad Wink

Publications and source records attributed to Konrad Wink.

5 recordsLinked to original sources
PubMed2006

[Design and method of clinical trials of drugs used in the therapy of stable peripheral arterial occlusive disease].

To prove the efficacy of the treatment of atherosclerotic stable peripheral arterial occlusive disease with drugs certain criteria are to be considered in the context of the design and performance of clinical trials. These criteria refer to the design of the study, randomisation, blinding, inclusion and exclusion criteria, definition of outcomes, methods of examination, sample size estimation, and evaluation of the results. If these criteria and conditions are not taken into consideration, false positive and negative results can arise. In the present study, the criteria to prove the efficacy of vasoactive substances in the treatment of atherosclerotic peripheral occlusive arterial diseases are presented.

Arterial Occlusive Diseases↗
PubMed2005

[Magnesium, acute myocardial infarction and reperfusion injury].

Coronary artery disease (CAD) ranks top with respect to morbidity and mortality in humans. Development of high-tech diagnostic and therapeutic strategies has greatly improved the prognosis of CAD and acute myocardial infarction (AMI) over the past decade. Data from experimental and clinical research have provided important information on the role of magnesium in CAD and AMI. In relation to duration and severity of CAD, an adrenaline induced systemic stress arises, which provokes enhanced magnesium requirements, because magnesium is the co-factor in ATP dependent myocardial metabolism. The success of pharmacological or mechanical intervention in AMI can be compromised by reperfusion injury, which is probably caused by myocardial calcium accumulation. Since magnesium blocks myocardial calcium influx, reperfusion injury might be diminished or even prevented by magnesium application. Thus, the common procedure of invasive cardiac intervention and intravenous magnesium administration before reperfusion could become the gold standard in treatment of AMI.

Humans↗
PubMed2003

Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?

The aim of this paper is to assess antihypertensive efficacy of b-blockers and their effects on cardiovascular morbidity and mortality and all-cause mortality in elderly patients with hypertension. Randomized placebo-controlled trials, trials with untreated controls, and trials comparing antihypertensive drugs were selected from the literature. The relative risk reduction of primary endpoints and 95% confidence intervals were calculated. There were six trials in which elderly patients were treated with beta-blockers for hypertension (three trials were placebo-controlled, one trial had untreated controls, and two trials compared antihypertensive drugs). There was no study with monotherapy of beta-blockers. In combination with diuretics, beta-blockers were superior to placebo and untreated controls in preventing cardiovascular events, especially strokes, but there was no superiority of beta-blockers to angiotensin-converting enzyme inhibitors and calcium antagonists in preventing cardiovascular morbidity and mortality and total mortality in elderly patients with hypertension. Beta-blockers are only efficacious in combination with diuretics in preventing cardiovascular morbidity and mortality in elderly patients with hypertension.

Adrenergic beta-Antagonists↗
PubMed2003

[Guidelines and methods for clinical investigation of drugs for treatment of stable angina pectoris].

To prove the antianginal efficacy of drugs in patients with stable angina pectoris the notice of certain criteria is necessary for the planning and performance for the clinical investigation of medicinal products. They consist of the study design, the randomization, blinding, inclusion and exclusion criteria, definition of endpoints, the performance of the study, the doses and dosing scheme, the methods of investigation, the sample size estimation and the evaluation of the results. If there will be not paid enough attention to these criteria and conditions false positive but also false negative results can arise. The criteria necessary for proving the antianginal efficacy in patients with stable angina pectoris will be presented.

Angina Pectoris↗